| Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study DA Hughes, K Nicholls, SP Shankar, G Sunder-Plassmann, D Koeller, ... Journal of medical genetics 54 (4), 288-296, 2017 | 440 | 2017 |
| Fabry disease: a review of current management strategies A Mehta, M Beck, F Eyskens, C Feliciani, I Kantola, U Ramaswami, ... QJM: An International Journal of Medicine 103 (9), 641-659, 2010 | 280 | 2010 |
| Respiratory chain complex V deficiency due to a mutation in the assembly gene ATP12 L De Meirleir, S Seneca, W Lissens, I De Clercq, F Eyskens, E Gerlo, ... Journal of medical genetics 41 (2), 120-124, 2004 | 252 | 2004 |
| International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up L Welling, LE Bernstein, GT Berry, AB Burlina, F Eyskens, M Gautschi, ... Journal of inherited metabolic disease 40, 171-176, 2017 | 197 | 2017 |
| Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease R Brouns, V Thijs, F Eyskens, M Van den Broeck, S Belachew, ... Stroke 41 (5), 863-868, 2010 | 162 | 2010 |
| Mutation of the iron-sulfur cluster assembly gene IBA57 causes severe myopathy and encephalopathy N Ajit Bolar, AV Vanlander, C Wilbrecht, N Van der Aa, J Smet, ... Human molecular genetics 22 (13), 2590-2602, 2013 | 139 | 2013 |
| The natural history of classic galactosemia: lessons from the GalNet registry ME Rubio-Gozalbo, M Haskovic, AM Bosch, B Burnyte, AI Coelho, ... Orphanet journal of rare diseases 14, 1-11, 2019 | 124 | 2019 |
| Deletion of PREPL, a gene encoding a putative serine oligopeptidase, in patients with hypotonia-cystinuria syndrome J Jaeken, K Martens, I François, F Eyskens, C Lecointre, R Derua, ... The American Journal of Human Genetics 78 (1), 38-51, 2006 | 98 | 2006 |
| Multiplex ligation‐dependent probe amplification to detect subtelomeric rearrangements in routine diagnostics L Rooms, E Reyniers, W Wuyts, K Storm, R Van Luijk, S Scheers, ... Clinical genetics 69 (1), 58-64, 2006 | 88 | 2006 |
| Neurocognitive outcome in tyrosinemia type 1 patients compared to healthy controls WG van Ginkel, R Jahja, SCJ Huijbregts, A Daly, A MacDonald, C De Laet, ... Orphanet journal of rare diseases 11, 1-9, 2016 | 82 | 2016 |
| Oral migalastat HCl leads to greater systemic exposure and tissue levels of active α-galactosidase A in Fabry patients when co-administered with infused agalsidase DG Warnock, DG Bichet, M Holida, O Goker-Alpan, K Nicholls, M Thomas, ... PLoS One 10 (8), e0134341, 2015 | 79 | 2015 |
| Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke R Brouns, R Sheorajpanday, E Braxel, F Eyskens, R Baker, D Hughes, ... Clinical neurology and neurosurgery 109 (6), 479-484, 2007 | 73 | 2007 |
| Dihydropyrimidinase deficiency: Phenotype, genotype and structural consequences in 17 patients ABP van Kuilenburg, D Dobritzsch, J Meijer, R Meinsma, JF Benoist, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1802 (7-8 …, 2010 | 69 | 2010 |
| Identifying non–Duchenne muscular dystrophy–positive and false negative results in prior Duchenne muscular dystrophy newborn screening programs: a review MA Gatheridge, JM Kwon, JM Mendell, G Scheuerbrandt, SJ Moat, ... JAMA neurology 73 (1), 111-116, 2016 | 68 | 2016 |
| Neonatal thyroid-stimulating hormone concentrations in Belgium: a useful indicator for detecting mild iodine deficiency? S Vandevijvere, W Coucke, J Vanderpas, C Trumpff, M Fauvart, ... PLoS One 7 (10), e47770, 2012 | 60 | 2012 |
| Phase I/II Trial of Liver–derived Mesenchymal Stem Cells in Pediatric Liver–based Metabolic Disorders: A Prospective, Open Label, Multicenter, Partially Randomized, Safety … F Smets, D Dobbelaere, P McKiernan, C Dionisi-Vici, P Broué, ... Transplantation 103 (9), 1903-1915, 2019 | 58 | 2019 |
| Impact of diagnosis and therapy on cognitive function in urea cycle disorders R Posset, AL Gropman, SCS Nagamani, LC Burrage, JK Bedoyan, ... Annals of neurology 86 (1), 116-128, 2019 | 57 | 2019 |
| Dietary management of urea cycle disorders: European practice S Adam, MF Almeida, M Assoun, J Baruteau, SM Bernabei, S Bigot, ... Molecular genetics and metabolism 110 (4), 439-445, 2013 | 57 | 2013 |
| A nonsense mutation in the 3-hydroxy-3-methylglutaryl-CoA lyase gene produces exon skipping in two patients of different origin with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency J PIÉ, N CASALS, CH CASALE, C BUESA, C MASCARÓ, A BARCELÓ, ... Biochemical Journal 323 (2), 329-335, 1997 | 46 | 1997 |
| Transatlantic combined and comparative data analysis of 1095 patients with urea cycle disorders—a successful strategy for clinical research of rare diseases R Posset, SF Garbade, N Boy, AB Burlina, C Dionisi‐Vici, D Dobbelaere, ... Journal of inherited metabolic disease 42 (1), 93-106, 2019 | 45 | 2019 |
